Brainstorm Cell Therapeutics Inc. BCLI
Set alert
As of Nov 2, 3:24 PM ET
- YTD
- +50.13%
- 1 year
- +27.03%
- Open
- 0.8282
- Prev close
- 0.8601
- Mkt cap
- 9.11M
- Vol
- 367
- Avg vol
- 23.41K
- EPS
- -0.93
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.8108
- High
- 0.8282
- Forward P/E
- -0.91
- Beta
- 0.39
- Short ratio
- 1.25
- Inst. own
- 13.90%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.70
- 200-d avg
- 4.88
- 1y target
- 23.45
News
2 months ago prnewswire.com
BrainStorm Executive Leadership to Participate in DUPHAT 2026; Executive Chairman Peter J. Pitts Invited to Deliver Two Keynote Addresses and Moderate Panel Sessions
Executive Chairman and Former FDA Associate Commissioner Peter J. Pitts to deliver keynote presentations on establishing an FDA Abraham Accords Office and restructuring NIH research grant models.
2 months ago prnewswire.com
BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update
NEW YORK, Aug. 14, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial…
-
3 months ago benzinga.com
Lunai Bioworks Signs Master Collaboration Agreement With BrainStorm Therapeutics; BioSymetrics Publishes Parkinson's Disease AI White Paper, Initial Data Expected In 1H 2027
New BioSymetrics Inc. white paper and executed Master Collaboration Agreement establish an integrated roadmap spanning AI-driven patient stratification, human translational validation, biomarker…
3 months ago prnewswire.com
BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive Chairman
Professor Jacob Frenkel Transitions to Senior Advisor Peter J. Pitts to lead NurOwn® into Phase 3b trial; advancing under the first Special Protocol Assessment ever granted for an ALS therapeutic…
5 months ago prnewswire.com
BrainStorm Cell Therapeutics Announces Publication Calling for Updated FDA Approaches to ALS, Rare Diseases and Regenerative Medicine
Former FDA Associate Commissioner Peter Pitts and BrainStorm's Chaim Lebovits argue that regulation must keep pace with advances in biomarkers, AI, cell therapy and precision medicine NEW YORK, June…
5 months ago prnewswire.com
BrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts to Board of Directors
Former Senior FDA Official Joins Board as Company Prepares to Initiate Historic Phase 3b ALS Trial Under Special Protocol Assessment NEW YORK, May 28, 2026 /PRNewswire/ -- BrainStorm Cell…
5 months ago prnewswire.com
BrainStorm Cell Therapeutics Announces Aggregate of $400,000 in Private Placements Priced at Premium to Market
$2.4 Million in H1 2026 Capital Raises Ahead of Phase 3b ENDURANCE Trial NEW YORK, May 19, 2026 /PRNewswire/ -- May 19, 2026 – BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of…
5 months ago prnewswire.com
BrainStorm Cell Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update
NEW YORK, May 15, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial…
6 months ago defenseworld.net
Comparing Brainstorm Cell Therapeutics (NASDAQ:BCLI) and Zealand Pharma A/S (OTCMKTS:ZLDPF)
Brainstorm Cell Therapeutics (NASDAQ: BCLI - Get Free Report) and Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) are both medical companies, but which is the superior business? We will contrast…
6 months ago defenseworld.net
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Shares Pass Above Two Hundred Day Moving Average – Here’s What Happened
Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI - Get Free Report)'s stock price passed above its two hundred day moving average during trading on Tuesday. The stock has a two hundred day moving…
7 months ago prnewswire.com
BrainStorm Cell Therapeutics Announces Full Year 2025 Financial Results and Provides Corporate Update
Strategic $2.0 million post year-end financing and re-rating of BCLI shares underscore market confidence Company highlights durable long-term survival in Expanded Access Program (EAP) cohort…
7 months ago defenseworld.net
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Stock Price Passes Above 200-Day Moving Average – Should You Sell?
Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI - Get Free Report)'s stock price passed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $0.65 and…
7 months ago defenseworld.net
Brainstorm Cell Therapeutics (BCLI) Expected to Announce Quarterly Earnings on Monday
Brainstorm Cell Therapeutics (NASDAQ: BCLI - Get Free Report) is anticipated to release its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect Brainstorm Cell Therapeutics…
8 months ago prnewswire.com
Brainstorm Cell Therapeutics Secures Second $1 Million Strategic Placement; Total $2 Million Raised In February
NEW YORK, Feb. 26, 2026 /PRNewswire/ -- Brainstorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced it has…
8 months ago prnewswire.com
Brainstorm Cell Therapeutics Announces $1 Million Strategic Financing at Premium to Market
NEW YORK, Feb. 20, 2026 /PRNewswire/ -- Brainstorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced it has…
11 months ago prnewswire.com
BrainStorm Cell Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update
NEW YORK , Nov. 14, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial…
1 year ago businesswire.com
Halper Sadeh LLC Encourages Brainstorm Cell Therapeutics Inc. Shareholders to Contact the Firm to Discuss Their Rights
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Brainstorm Cell Therapeutics Inc. (OTCMKTS: BCLI) breached their…
1 year ago seekingalpha.com
Brainstorm Cell Therapeutics Inc. (BCLI) Q2 2025 Earnings Call Transcript
Brainstorm Cell Therapeutics Inc. (OTC:BCLI) Q2 2025 Earnings Conference Call August 14, 2025 8:30 AM ET Company Participants Alla Patlis - Interim CFO & Controller Chaim Lebovits - President & CEO…
1 year ago prnewswire.com
BrainStorm Cell Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update
Conference call and webcast scheduled for 8:30 a.m. Eastern Time Today, Thursday, August 14, 2025 NEW YORK , Aug. 14, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading…
1 year ago prnewswire.com
BrainStorm to Announce Second Quarter Financial Results and Provide a Corporate Update
Call Scheduled for August 14, 2025, at 8:30 AM Eastern Time NEW YORK , Aug. 8, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
1 year ago prnewswire.com
BrainStorm Cell Therapeutics Announces Nasdaq Delisting and Transition to OTCQB
NEW YORK , July 17, 2025 BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) today announced that it has received a delisting notification from The Nasdaq Stock Market LLC, informing the company that…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
-
2 years ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
-
2 years ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
-
2 years ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
2 years ago benzinga.com
Why Biophytis Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket
Shares of Biophytis S.A. (NASDAQ: BPTS) rose sharply in today’s pre-market trading after reporting FY23 results.
-
2 years ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
-
2 years ago benzinga.com
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news.
-
2 years ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
-
2 years ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
-
2 years ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
-
2 years ago benzinga.com
Why Reneo Pharmaceuticals Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM) shares rose sharply during Wednesday’s session after Concentra sent an acquisition proposal to acquire 100% of equity of the company for $1.80 per…
-
2 years ago benzinga.com
Earnings Scheduled For November 14, 2023
Companies Reporting Before The Bell • CureVac (NASDAQ:CVAC) is likely to report quarterly loss at $0.24 per share on revenue of $18.00 million.
-
3 years ago benzinga.com
Why Plus Therapeutics Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket
Gainers
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
Tuesday saw 132 companies set new 52-week lows.
-
3 years ago benzinga.com
Why SeaStar Medical Holding Shares Are Trading Higher By Around 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Blue Apron Holdings, Inc. (NASDAQ: APRN) climbed 133.5% to $12.82 after the company announced an agreement to be acquired by Wonder Group for $13 per share.
-
3 years ago benzinga.com
Why CarMax Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Bionomics Limited (NASDAQ: BNOX) shares jumped 308% to $4.00 after the company announced the ATTUNE trial met its primary endpoint showing BNC210 treatment led to a statistically significant…
-
3 years ago benzinga.com
Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2023
Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2023
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 386 stocks made new 52-week lows.
-
3 years ago benzinga.com
Why Brainstorm Cell Therapeutics Shares Are Trading Lower By 33%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares jumped 308% to $2.71 after the company announced pre-clinical gliblastoma results with its lead candidate, TTX-MC138.